Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z D Chen

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
British Journal of Cancer|March 7, 2013
A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditionsZ-q Xu, Y Y Broza, R Ionsecu, et al.
European Journal of Cancer Care|April 11, 2017
Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III studyL Q Yang, X C Sun, S K Qin, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|April 23, 2025
[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex<sup>®</sup> for patients with premenopausal breast cancer]X Y Shao, Q Y Zhang, Z F Niu, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
British Journal of Cancer|March 7, 2013
A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditionsZ-q Xu, Y Y Broza, R Ionsecu, et al.
European Journal of Cancer Care|April 11, 2017
Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III studyL Q Yang, X C Sun, S K Qin, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|April 23, 2025
[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex<sup>®</sup> for patients with premenopausal breast cancer]X Y Shao, Q Y Zhang, Z F Niu, et al.
Pageof 6